Rebecca DeMoor

Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study

Chloe Orkin, Enrique Bernal, Darrell H. S. Tan et al. · The Lancet HIV · 2021 · 142 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure

Chloe Orkin, Jonathan Schapiro, Carlo Federico Perno et al. · Clinical Infectious Diseases · 2023 · 124 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the <i>vastus lateralis</i> (lateral thigh) muscles of healthy adult participants

Kelong Han, Hakop Gevorkyan, Jafar Sadik Shaik et al. · Antimicrobial Agents and Chemotherapy · 2023 · 20 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings

Celia Jonsson‐Oldenbüttel, Jade Ghosn, Marc van der Valk et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2024 · 17 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacotherapy +15

Impact of Reduced Preincision Antibiotic Infusion Time on Surgical Site Infection Rates

Neil R. Malhotra, Matthew Piazza, Rebecca DeMoor et al. · Annals of Surgery · 2018 · 14 citations

Medicine, Perioperative Medicine, Surgery +17